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Extensive lymphatic malformations (LMs) of the head and neck region may require
tracheostomy to secure the airway. Treatment of these life-threatening LMs is usually
multimodal and includes sclerotherapy and surgery, among others. Recently, systemic
therapy with sirolimus has been introduced as an effective treatment for venous
and lymphatic malformations; its efficacy and safety profile in patients with extensive
LM requiring tracheostomy are, however, as yet not fully known. We performed a
retrospective, multicenter review and identified 13 patients with an extensive LM of
the head and neck region, who previously underwent placement of tracheostomy and
subsequently received sirolimus treatment with the aim to improve the local respiratory
situation and remove the tracheostomy. Under sirolimus therapy, tracheostomy could be
reversed in 8/13 (62%) patients, a further 2/13 (15%) patients improved markedly, and
removal of the tracheostomy was planned at the time of writing, while 3/13 (23%) patients
showed insufficient or absent response to sirolimus, rendering tracheostomy reversal
not feasible. The median duration of sirolimus treatment until removal of tracheostomy
was 18 months (range, 8 months to 5.6 years). Adverse events of sirolimus therapy
were common [10/13 (77%) patients], yet the majority of these were mild [9/10 (90%)
patients] and only one severe adverse event was recorded, with ulceration and necrosis
at a catheter insertion site. In conclusion, sirolimus can be considered an effective
and safe salvage treatment in patients with extensive LM even after placement of a
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tracheostomy, as closure of the latter was possible in the majority of patients (62%) of
our retrospective cohort. A better understanding of when to start sirolimus therapy, of
the duration of treatment, and of factors allowing the prediction of treatment response
will require further investigation.
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INTRODUCTION
Extensive lymphatic malformations (LMs) of the head and
neck region can be life-threatening due to infiltration of vital
structures of the airway and may require early intubation, e.g.,
by ex utero intrapartum treatment (EXIT) procedure, mechanical
ventilation, and even long-term placement of tracheostomy to
secure the airway and/or feeding tubes to realize nutrition.
The majority of extensive cervical LMs are diagnosed pre- or
post-natally and generally require treatment early during the
neonatal period. Treatment modalities depend on the extent of
macrocystic, microcystic, or mixed components of the LM and
include multimodal approaches such as repetitive sclerotherapy,
surgical resection, and laser therapy with often unsatisfying
results. The complexity and the variable presentation of extensive
head and neck LM complicate the understanding of the natural
history and the response to different treatment modalities of
this rare disease. Several systems for staging and outcome
measures have been proposed (1, 2). Sirolimus has recently
been introduced as an alternative systemic treatment option
in complex vascular anomalies (3, 4) and it has been further
demonstrated that neonates with extensive LM benefit from low-
dose systemic treatment with sirolimus immediately after birth,
while experiencing only mild side effects (5).
Sirolimus is an mTOR inhibitor and blocks downstream
signaling of the PI3K/AKT/mTOR pathway that governs
physiological vascular development and angiogenesis (6, 7). In
pediatric patients, experience with sirolimus treatment as an
immunosuppressant agent is scarce and it has been gained
mainly from kidney transplantation patients (8). In the context
of vascular anomalies, and specifically in pediatric patients, the
efficacy and safety of sirolimus, however, is still a matter of
ongoing research. Published data are promising (3–5, 9–11),
yet the drug still lacks regulatory approval for the treatment of
vascular anomalies (3, 5).
In this multicenter retrospective study, we analyzed
our experience with 13 patients treated with sirolimus in
multidisciplinary vascular anomaly centers of the VASCA
working group of the European Reference Network VASCERN
after insufficient standard therapies. All patients required
tracheostomy due to a life-threatening extent of an LM of the
Abbreviations: AE, Adverse event; AKT, Protein kinase B; EU, European Union;
LM, Lymphatic malformation; ICU, Intensive care unit; MRI, Magnetic resonance
tomography; mTOR, Mechanistic target of rapamycin; OK432, Picibanil;
PI3K, Phosphatidylinositol 3-kinase inhibitor; PIK3CA, Phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha; PROS, PIK3CA-related overgrowth
syndrome; SAE, Severe adverse event; VA, Vascular anomaly; VASCERN,
European Reference Network on Rare Multisystemic Vascular Diseases; VEGFA,
Vascular endothelial growth factor A.
head and neck region with compression of the airway. The
study focused on efficacy with respect to successful reversal of
tracheostomy and safety of the drug.
MATERIALS
We performed a retrospective multicenter chart review of 13
patients with extensive LM of the head and neck region that had
previously undergone placement of a tracheostomy at a median
age of 1 month (range, 1 day to 45 months). Patients suffered
from an isolated LM of the head and neck region and were
not subjected to an underlying complex lymphatic anomaly. All
patients were treated with sirolimus between January 2013 and
December 2020 (treatment is still ongoing in nine patients) with
the aim to remove the tracheostomy. We assessed the efficacy,
which was defined as achieving removal of the tracheostomy,
and the safety of sirolimus, defined as the occurrence of adverse
events (AEs). Patients and their guardians were informed of the
risks, benefits, and therapeutic alternatives before treatment with
off-label sirolimus. This study is covered by the ethical committee
number Freiburg 464/19.
Patient Data
Analyzed patient variables included basic patient characteristics,
location and extent of the LM, symptoms, other previous and
concomitant treatment modalities and their effects, treatment
with sirolimus, dosage and trough level targets as well as
treatment duration and response, and AEs and severe adverse
events (SAEs). The definition of AEs was according to Good
Clinical Practice (GCP) rules and included any untoward
medical occurrence, with SAE including events that resulted in
death, were life-threatening, required inpatient hospitalization
or caused prolongation of existing hospitalization, resulted in
persistent or significant disability/incapacity, might have caused
a congenital anomaly/birth defect, or required intervention
to prevent permanent impairment or damage. We used the
following grading system: grades 1 and 2 represent non-SAEs,
and grades 3–5 represent SAEs: 3 for severe or medically
significant but not immediately life-threatening, 4 for life-
threatening, and 5 for death.
Treatment
Treatment with sirolimus was proposed to promote reversal of
tracheostomy in patients with extensive LM of the head and
neck region after results of other treatment modalities were not
satisfactory. Treatment with sirolimus resulted in reversal of
tracheostomy after amedian of 18months (range, 8months to 5.6
years) of treatment initiation. The median age at tracheostomy
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TABLE 1 | Summary of clinical patient characteristics and treatment other than and prior to sirolimus (order according to treatment response).
Treatment modalities































P01 F At birth Tongue, floor of mouth,
mandibular, submentally up to left
ear, neck
RFA
P02 M At birth Right cervical region extending
intrathoracically
P03 M Intrauterine Face, neck, mediastinum
extending to carina
P04 M Intrauterine Right side of the face and neck,
right parapharyngeal involvement
P05 F 1m Base of mouth, oropharynx,
anterior cervical region, both
parapharyngeal spaces and left
temporal fossa
P06 F At birth Tongue
P07 M At birth Extensive cervical and facial
region, tongue
P08 M At birth Lung, pleura with pleural and




P09 F At birth Tongue, floor of mouth, partial
trachea obstruction, face, neck
P10 M Intrauterine Floor of mouth, larynx, neck
P11 F At birth Extensive neck, laryngeal cleft with
compression of trachea
P12 F At birth Tongue, floor of mouth,
mandibular, cheeks
P13 M Intrauterine Tongue, floor of mouth,
mandibular, neck and larynx
F, female, M, male, m, month, RFA, radiofrequency ablation.
removal was 2 years (range, 11 months to 6 years) and the
administered dose of sirolimus was adapted according to target
trough levels (5–15 ng/ml), respectively. Efficacy criteria included
clinical improvement of symptoms and removal of tracheostomy.
Data Analysis
A retrospective data analysis of 13 patients treated at European
Reference Centers was performed. Data are presented




Tracheostomy had been performed in 13 patients with life-
threatening LM of the head and neck region prior to treatment
with sirolimus. One patient (P07) had additionally received
a gastrostomy simultaneously with the placement of the
tracheostomy at the age of 5 months to facilitate feeding. Six
(46%) patients were female, and seven (54%) were male. The
LM was diagnosed prenatally in four (31%) patients, at birth in
eight (62%) patients, and at 1 month of age in 1 (8%) patient. All
patients had acute or sub-acute obstruction of the upper airway
caused by the LM, which also involved the tongue and larynx in
six patients (46%) and the mediastinum in two patients (15%).
Prior to treatment with sirolimus, 10 (77%) patients received
sclerotherapy with OK432, doxycycline, or bleomycin; 6 (46%)
received surgical resection; and 5 (38%) received laser therapy
(Tables 1, 2).
Tracheostomy and Treatment With
Sirolimus
Tracheostomy was performed at a median age of 1 month (range,
1 day to 45 months). In two patients (P05 and P13), an EXIT
procedure was performed, while the other patients were born by
elective cesarean section or per natural route and successfully
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TABLE 2 | Summary of tracheostomy and treatment with sirolimus (order according to treatment response) and associated adverse events.
Patient ID Age at
placement of
tracheostoma























from ages 1m to






due to increase of
LM PIK3CA
mutation, switch
to alpelisib at age
17 y, 6m ongoing
monthly avastin
since age 4 y
02 9m 10m 5–10 Mild infections 16, Still ongoing Removal, 2 y,
2m





20, Still ongoing removal, 2 y,
10m
04 1m; 5 y 9 y 5–10 Lymphopenia 12, Still ongoing Removal,
10 y, 10m
05 1m 3 y, 1m 4–5 Mild infections 10, Still ongoing Removal, 3 y,
11m
06 6w 15m 3.5–5.6 – 21, Still ongoing Removal, 3 y
07 5m 11 y, 11m 5–10 Skin toxicity ◦ I/II, mild
infections








09 14 d 1m 3.8–4.7 Mild infections 32, Still ongoing Removal
planned
10 1 d 2m 5–10 Mild infections 31, Still ongoing Removal
planned
11 2m 3 y, 9m 3.3–4.6 Hypophosphatemia,
mild infections
23, Still ongoing Still required
12 2 d 18 y 10–15 Recurrent FUO 7 Still required
13 2 d 5 y 5–10 – 5 Still required
m, months; y, years; FUO, fever of unknown origin; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha.
stabilized during the neonatal first aid. Dosing of sirolimus
depended on age at treatment initiation, which varied widely
with a median of 37 months (range, 1 month to 18 years). Three
patients (P05, P10, and P13) were started early on sirolimus at
1 (P10) and 2 months (P05 and P13). P05 started with low-
dose sirolimus including a 50% reduction of the recommended
dose of 0.8 mg/m2/12 h (3, 5). All other patients received the
recommended dose of 0.8 mg/m2/12 h. Following initiation of
sirolimus therapy, reversal of tracheostomy was accomplished in
eight patients (62%, P1–P8) after a median of 18 months (range,
8 months to 5.6 years) of treatment with sirolimus. The median
age at tracheostomy reversal was 2 years (range, 11 months to
6 years). In another two responding patients (P09 and P10),
removal of tracheostoma was planned at the time of writing. One
patient (P11) experienced clinical stabilization with decrease in
pain and infections, but without relevant size reduction of the
LM, so that removal of the tracheostomy was not an option. In
two patients (P12 and P13), sirolimus was discontinued early
after 5 and 7 months of therapy for lack of clinical benefit
(Figure 1, Table 2).
The clinical benefit of sirolimus therapy was not restricted
to the removal of the tracheostomy. For instance, treatment
response in P01 included a significant decrease in the size of
the tongue that enabled the patient to regain the ability to
close her mouth completely (MRI images Figures 1A–D, 2).
In 9/13 (69%) patients (P02–P06 and P08–P11), treatment
with sirolimus is ongoing, with intermittent but unsuccessful
attempts to taper and discontinue the drug. Additional medical
treatments were performed in two patients. P07 was found
to harbor a somatic PIK3CA mutation and was started
on alpelisib—an inhibitor of the phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha—with the aim
to sustain a stable clinical condition following removal of
tracheostomy. Sirolimus was discontinued in this patient after
a total of 67 months of treatment initiation simultaneously
with the introduction of alpelisib and he remained in a
stable respiratory condition thereafter. P08 had an incomplete
response to 8 months of sirolimus therapy; bevacizumab—
an inhibitor of the vascular endothelial growth factor A
(VEGFA)—was added and the tracheostomy could be removed
after 5 months of simultaneous treatment. Both sirolimus
and bevacizumab are still ongoing in this patient for clinical
stabilization (Figures 1, 2).
Treatment with sirolimus is ongoing in a total of 9/13
(69%) patients (P02–P06 and P08–P11). Of these nine patients,
treatment was continued in six patients after successful removal
of tracheostomy (P02–P06 and P08). Two patients (P09 and P10)
showed size reduction of the LM and clinical stabilization. In
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FIGURE 1 | MRI images of P01 before (A,B) and after (C,D) treatment with sirolimus shows marked size reduction of the LM affecting the tongue and the floor of the
mouth (arrows). As a result of the sirolimus therapy, the patient was able to completely close her mouth prior to reversal of the tracheostomy (C,D). (E) Pie chart
depicting the distribution of patients: in 8/13 patients, sirolimus showed complete response and the tracheostomy could be reversed; 2/13 patients showed good
response with planned removal of the tracheostoma; and in 3/13 patients, the tracheostomy could not be removed due to insufficient response. (F) Kaplan–Meier
curve illustrating the percentage of patients (62%), in whom tracheostomy could be removed in months after treatment initiation with sirolimus.
P09, sirolimus was intermittently discontinued due to relapsing
mild infections resulting in recurrent size increase of the LM.
P10 showed a treatment response with adequate size reduction,
cessation of bleeding and inflammation resulting in respiratory
stabilization. As mentioned above, reversal of the tracheostomy
is now anticipated in both patients. P11 experienced clinical
improvement without size reduction under sirolimus but the
response was insufficient for reversal of the tracheostomy
(Table 2).
AE under treatment with sirolimus occurred in 10/13 (77%)
patients. They included mild viral infections in 7/10 (70%)
patients (P02, P03, P05, P07, and P09–P11), lymphopenia
in 2/10 (20%) patients (P04 and P08), and low-grade skin
toxicity, hypophosphatemia, as well as recurrent mild fever of
unknown origin in 1/10 (10%) patients each (P07, P11, and
P12). There was one SAE with ulceration and necrosis at a
pigtail catheter insertion site necessitating hospitalization and
discontinuation of sirolimus therapy (P03). In addition, the
same patient suffered from inflammation and scarring at the
tracheostoma that required repetitive excisions of a substomal
intratracheal lump 15 and 28 months after sirolimus treatment
initiation and eventually a reconstruction of the trachea with a
cartilage graft.
DISCUSSION
To the best of our knowledge, this is the first study to assess the
efficacy of sirolimus in patients requiring tracheostomy for life-
threatening LM of the head and neck region. The main findings
of this study are that (i) sirolimus is an effective salvage treatment
in patients with an extensive LM of the head and neck region
requiring tracheostomy, (ii) tracheostomy may be removed in
a majority of patients under sirolimus therapy, and (iii) AEs
under sirolimus therapy are common, yet well-controllable if
monitored carefully.
In patients undergoing tracheostomy due to acute
compression of vital structures by extensive LM of the head and
neck region, treatment with sirolimus proved to be an effective
salvage option with reversal of tracheostomy in a significant
number of patients (8/13, 62%) with an additional 2/13 (15%)
patients planned for tracheostomy reversal. One of these patients
(P07) received alpelisib following removal of tracheostomy after
long-term treatment with sirolimus and its discontinuation after
5.6 years. While preliminary data are promising in patients with
PROS diseases (12), the role of alpelisib in the treatment of
head and neck LM remains to be defined. Another patient (P08)
received bevacizumab in addition to sirolimus, and both drugs
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FIGURE 2 | Overview of patient groups differentiated by treatment response (blue), good response (yellow), and insufficient treatment response (P11, P12, and P13)
(red). The graph further illustrates total treatment duration with sirolimus, time to removal of tracheostomy after sirolimus treatment initiation, as well as (simultaneous)
treatment with the PI3K inhibitor alpelisib and the VEGFA inhibitor bevacizumab (in months).
are still ongoing to stabilize the patient’s respiratory condition.
Bevacizumab is a monoclonal antibody and, besides its well-
known inhibitory effect on tumor angiogenesis, attenuates
VEGFA-mediated signaling in complicated lymphatic anomalies
(CLAs) (13, 14). In our cohort, treatment with sirolimus resulted
in relevant clinical and radiological improvement of the LM, as
was expected from the literature. Optimal dosing and (serum)
target trough levels considering individual patient characteristics
have been evaluated recently but are still a matter of an ongoing
debate (3, 5). According to our data, we did not see a correlation
between dosage, target trough levels (2–15 mg/ml), initial size
of the lesion, gender, or AE and treatment response in our
relatively small patient cohort. In previous publications, trough
levels of 10–15 ng/ml were recommended (3, 5). In fact, growing
experience with sirolimus therapy in the field of vascular
anomalies in recent years has demonstrated that treatment
response does not improve with increased sirolimus trough
levels (15). Interestingly, the median age at treatment initiation
of sirolimus with 37 months in all patients and 26 months in
successfully treated patients (P01–P10) was younger than in
those with insufficient treatment responses (P11–P13) with 60
months (Tables 1, 2). Even though these data are not significant,
they suggest that treatment initiation of sirolimus at a young
age might be beneficial with regard to treatment response rates
[10/13 (77%) responders vs. 3/13 (23%) non-responders]. The
safety of early treatment initiation has previously been shown in
a small cohort of neonates (5).
While 3/8 patients (38%) achieved removal of tracheostomy
within 1 year, this took longer in the remaining patients (up
to 67 months). We propose that this may be due to the
gradual reduction in treatment response as well as the need
for a stable clinical status over a longer time period before
tracheostomy removal. It is important to communicate a possibly
long treatment duration with patients and their families.
AEs were common but almost exclusively non-severe and
within the spectrum of expected side effects of sirolimus. We
would attribute the only SAE in our cohort (necrosis at a
pigtail catheter insertion site and inflammation and scarring
at the tracheostoma) to an expectedly impaired wound healing
under sirolimus treatment. The safety profile of sirolimus in the
context of vascular anomalies (9–11) is similar to what has been
demonstrated earlier in pediatric kidney transplantation patients
(8, 16), with SAEs being rarely reported especially in vascular
anomalies (9). However, the exact spectrum of side effects of
sirolimus in this special patient population is, as yet, not fully
known and needs further investigation. Other considerations,
e.g., hypothetical long-term effects of immunosuppression with
sirolimus on a developing immune system of an infant, should
also be assessed further in the future.
Most viral infections under sirolimus involved the respiratory
tract, as would be expected in a pediatric patient cohort.
Furthermore, LM of the head and neck region may additionally
compress relevant anatomic structures of the airway, thereby
further predisposing to lung infections. Along these lines,
vaccines in patients with complex vascular anomalies treated
with sirolimus and therefore susceptible to infections are to be
critically reconsidered (9). Whenever possible, vaccines should
be completed before treatment initiation with sirolimus. As this
might not be feasible in all patients (e.g., neonates), inactivated
vaccines may be administered during therapy, despite the fact
that the immunogenic response might not be optimal. Although
we generally recommend delaying immunization with attenuated
life vaccines until the patient is off sirolimus therapy, timing
may not be feasible in patients who require lengthy sirolimus
therapy for clinical stabilization as was the case in four of
our patients in this study. To illustrate, P02 had not received
attenuated vaccines as sirolimus was started at the age of 10
months. He developed severe epidemic parotitis after 3 years and
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9 months of treatment with sirolimus at the age of 4 years and
7 months. Due to extensive cervical swelling and a secondary
inflammatory response of the LM, the patient came close to
necessitating mechanical ventilation again. This exemplifies that
individual consideration of the risks and benefits of inactivated
and attenuated vaccines in these vulnerable patients is critical.
A weakness of our study is its retrospective nature and
the lack of a control group. Extensive cervical LM with
acute or subacute airway obstructing are extremely rare and
life-threatening disease states requiring prompt and often
multimodal treatment. Alternative methods to collect data on
this highly selected patient cohort were not feasible under
these conditions. With the abovementioned limitations in mind,
it is difficult to assess the natural history as well as the
value of selected treatment modalities in patients with life-
threatening head and neck LM. On the basis of our data, we
hypothesize that sirolimus may have the potential to significantly
contribute to the improvement of our patient’s life-threatening
condition. We are aware that the efficacy of sirolimus in our
patients may be at least in part confounded by the multimodal
treatments prior to and during sirolimus therapy and that
the naturally increasing size of the airway may have further
impacted tracheostomy removal, as has been reported for other
indications of tracheostomy in pediatric patients (17). However,
the rate of successful tracheostomy removal in our patient
cohort treated with sirolimus is encouraging and we expect
that multimodal treatment approaches including sirolimus,
sclerotherapy, and surgery at interdisciplinary vascular anomaly
centers will increasingly be applied in the future and may
contribute to an improved prognosis of severely affected patients.
To refine the treatment with sirolimus, many open questions
remain to be answered such as dosage, treatment duration, and
tapering of sirolimus. Yet, this should not discourage physicians
from treating severely affected patients with sirolimus, even after
extensive pre-treatment. Sirolimus is still considered an “off-
label” therapy in complex vascular anomalies. We hope that
our study will pave the way for future international studies
conducted in a well-planned manner, for instance, by comparing
two drugs inhibiting the PIK3CA/mTOR pathway, e.g., sirolimus
and alpelisib, to further delineate the value of these drugs in the
treatment of extensive LM of the head and neck region.
CONCLUSIONS
Sirolimus is an “off-label” treatment that can be considered
an efficient and safe salvage treatment option in patients with
complex, life-threatening and treatment-resistant LM of the
head and neck requiring tracheostomy, as it significantly (62%
in our series) reduces the need for tracheostomy following
size reduction of LM and respiratory stabilization. AEs under
sirolimus were common (77%), but mostly remained mild
and controllable if monitored carefully. Adequate selection
of patients and timing of treatment with sirolimus require
further investigation.
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